Creatinine (Crea) Gen.2 (Sarcosine Oxidase Method)    

A Groundbreaking Solution for Antidrug Interference    


   

微信图片_20190520110131.png                            


   

                             

A Groundbreaking Solution for Antidrug Interference    

Efficiently eliminate the interferences of calcium dobesilate and etamsylate in the sample    

Calcium dobesilate and etamsylate will result in lower results tested by enzymatic creatinine and affect clinical judgments.    


   

Drug  Name  Effectiveness  Clinical ApplicationInterferences
Calcium DobesilateVascular Protective AgentDiabetic Microangiopathy, Diabetic Eye Diseases, DN, DPN, Elderly Coronary Heart Disease Angina.Enzymatic creatinine reagents will be negatively interfered. The deviation of results will be up to -60%, with the increasing of the drug concentration, even worse for those patients with poor renal function.
EtamsylateHemostatic DrugBleeding prevention before and after surgery, bleeding caused by factors of blood and blood vessel, such as thrombocytopenic purpura, cerebral hemorrhage, gastrointestinal, urinary tract, fundus, gum, and nose bleeding, etc.Enzymatic creatinine reagents will be negatively interfered. The deviation of results will be up to -70%, with the increasing of the drug concentration.

                             

When the concentration of calcium dobesilate is not greater than 250 mg/L, the test of Crea Gen.2 won’t be interfered.    

1565330940175285137.jpg                              

When the concentration of etamsylate is not greater than 250 mg/L, the test of Crea Gen.2 won’t be interfered.

未标题-2.jpg  

 

                               

A Groundbreaking Solution for Antidrug Interference

Cooperated to develop with PUMCH and obtained the national invention patent.

微信图片_20190505112325.jpg